Skip to content
  • Home
  • About
  • Portfolio
  • Contact Us
Menu
  • Home
  • About
  • Portfolio
  • Contact Us

Portfolio/ Regentis Biomaterials

Regentis Biomaterials is a tissue repair company focused on developing and commercializing of innovative hydrogel platform for the repair of damaged tissue. The Gelrin hydrogel platform is the foundation for the company’s flagship product, GelrinC, a biodegradable implant for cartilage regeneration. The product received ISO certification and is currently undergoing clinical trials in Germany, Belgium and Israel.

Regentis is funded by Crossroad Fund, Medica Venture Partners, SPCVitalife, DSM Ventures and the Technion Investment Opportunities Fund.

www.regentis.co.il

Regentis

REGENTIS BIOMATERIALS EXPANDS SAGE CLINICAL TRIAL OF GELRINC™ FOR KNEE...

PRINCETON, NJ and OR AKIVA, Israel – October 23, 2018 – Regentis Biomaterials todayannounced it has expanded the SAGE clinical...
Regentis

TRIA Orthopedics First in Minnesota to Test Breakthrough GelrinC™ Implant...

MINNEAPOLIS, Minn. – Nov. 27, 2018 – Regentis Biomaterials today announced that Twin Cities-based TRIA Orthopedics is the first in...

Contact us

Contact us for any questions and we will get back to you as soon as possible

2019 Crossroad Fund | BIT Enterprises Ltd.